Free Trial
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Madrigal Pharmaceuticals logo
$298.48 -1.67 (-0.55%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$298.48 0.00 (0.00%)
As of 07/3/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Key Stats

Today's Range
$298.00
$304.00
50-Day Range
$267.56
$340.80
52-Week Range
$200.63
$377.46
Volume
108,674 shs
Average Volume
358,926 shs
Market Capitalization
$6.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$420.63
Consensus Rating
Moderate Buy

Company Overview

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

MDGL MarketRank™: 

Madrigal Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 571st out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Madrigal Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Madrigal Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($23.47) to ($12.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Madrigal Pharmaceuticals is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Madrigal Pharmaceuticals is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Madrigal Pharmaceuticals has a P/B Ratio of 8.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Madrigal Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    23.81% of the float of Madrigal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Madrigal Pharmaceuticals has recently increased by 6.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Madrigal Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Madrigal Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.81% of the float of Madrigal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Madrigal Pharmaceuticals has recently increased by 6.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Madrigal Pharmaceuticals has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Madrigal Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    Only 5 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.50% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Madrigal Pharmaceuticals' insider trading history.
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

Madrigal Pharma (MDGL) Share News Today - Investing.com UK
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

MDGL Stock Analysis - Frequently Asked Questions

Madrigal Pharmaceuticals' stock was trading at $308.57 at the start of the year. Since then, MDGL stock has decreased by 3.3% and is now trading at $298.4850.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings data on Thursday, May, 1st. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.62) by $0.30. The biopharmaceutical company had revenue of $137.25 million for the quarter, compared to analyst estimates of $112.79 million. Madrigal Pharmaceuticals had a negative net margin of 123.38% and a negative trailing twelve-month return on equity of 50.54%.
Read the conference call transcript
.

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/01/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
Employees
90
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$420.63
High Stock Price Target
$469.00
Low Stock Price Target
$350.00
Potential Upside/Downside
+40.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$465.89 million
Net Margins
-123.38%
Pretax Margin
-123.38%

Debt

Sales & Book Value

Annual Sales
$180.13 million
Price / Cash Flow
N/A
Book Value
$34.59 per share
Price / Book
8.63

Miscellaneous

Free Float
17,429,000
Market Cap
$6.63 billion
Optionable
Optionable
Beta
-1.05

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:MDGL) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners